BioSpace News Archive

The global gene editing market size is estimated to reach around USD 29.93 billion by 2032, increasing from USD 6.94 billion in 2022.

Cyclacel Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) noted today that its Founded Entity, Karuna Therapeutics, Inc., and (Nasdaq: KRTX) Bristol Myers Squibb (NYSE: BMY) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition.

The United States has the highest maternal mortality rate among developed nations – with worse health outcomes for Black women and other minority groups.

IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has entered into a loan agreement of up to SEK 55 million issued by Formue Nord Fokus A/S.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

Cellectis held a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company’s 2023 Inducement Plan.